BioCentury | Oct 31, 2011
Company News

Accium BioSciences Inc., PrognosDx deal

...The companies partnered to develop and commercialize predictive histone biomarkers tests using PrognosDx's epigenetic technology with...
...Accium's accelerator mass spectrometry technology. Details were not disclosed. Accium BioSciences Inc. , Seattle, Wash. PrognosDx Health Inc....
BioCentury | Jun 22, 2009
Company News

PrognosDx, University of California deal

...PrognosDx received exclusive, worldwide rights to the university's IP covering histone modification technology. PrognosDx is developing...
...for cancer and other diseases based on histone modification patterns. Further terms were not disclosed. PrognosDx Health Inc....
Items per page:
1 - 2 of 2
BioCentury | Oct 31, 2011
Company News

Accium BioSciences Inc., PrognosDx deal

...The companies partnered to develop and commercialize predictive histone biomarkers tests using PrognosDx's epigenetic technology with...
...Accium's accelerator mass spectrometry technology. Details were not disclosed. Accium BioSciences Inc. , Seattle, Wash. PrognosDx Health Inc....
BioCentury | Jun 22, 2009
Company News

PrognosDx, University of California deal

...PrognosDx received exclusive, worldwide rights to the university's IP covering histone modification technology. PrognosDx is developing...
...for cancer and other diseases based on histone modification patterns. Further terms were not disclosed. PrognosDx Health Inc....
Items per page:
1 - 2 of 2